Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Intensive Chemo for Newly Diagnosed AML
NCT05356169Phase 3Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05356169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356169.